1278PHealth-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (23rd October 2018) - Coens, C; Bottomley, A; Blank, C U; Mandala, M; Long, G V; Atkinson, V G; Dalle, S; Haydon, A; Lichinitser, M; Khattak, A; Carlino, M S; Sandhu, S K; et al.